In our cohort of LC-IPF patients, those with a neuroendocrine component, advanced-stage disease, and with more than two metastatic sites had significantly higher serum PCT levels in comparison to those with a non-endocrine component, stages I-III disease, and less than two metastatic sites, respectively. This evidence concerns the gene CALCA and idiopathic pulmonary fibrosis.